Eli Lilly, the makers of Zepbound, gained FDA approval for its drug orforglipron, sold under the brand name Foundayo, on April 1, 2026, following Novo Nordisk, which received approval for the Wegovy pill in December 2025
The product is: Stimulant-free Vegan-friendly Free from artificial sweeteners or fillers Formulated in cGMP-compliant facilities The official website now features an expanded FAQ, ingredient breakdowns, and references to scientific research supporting the physiological roles of the featured compounds
However, noticeable weight loss may not begin until individuals reach their maintenance dose
This incentivized higher patient turnover, increased testing, and upselling services